Moneycontrol PRO
LAMF
LAMF

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang

    Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.

  • Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher

  • Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher

  • Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher

  • Cadila Healthcare Q1 PAT seen up 63.9% YoY to Rs 744 cr: KRChoksey

  • Cadila HC Q1 PAT seen up 10.7% YoY to Rs 502.5 cr: ICICI Direct

  • Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan

  • Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher

  • Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay

  • Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher

  • Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher

  • Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

  • Cadila Healthcare Q3 PAT may dip 12.8% YoY to Rs. 473.7 cr: ICICI Direct

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

  • Cadila Healthcare Q2 PAT seen up 4.8% YoY to Rs. 530 cr: HDFC Securities

  • Cadila Q2 PAT may dip 23.3% YoY to Rs. 386 cr: Sharekhan

  • Cadila Healthcare Q2 PAT may dip 25.4% YoY to Rs. 375.4 cr: ICICI Direct

  • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

  • Global brokerages upgrade these 6 stocks to buy post Q4 results

  • Cadila Healthcare Q4 PAT seen up 36.5% YoY to Rs. 530 cr: HDFC Securities

  • Cadila Healthcare Q4 PAT seen up 39.7% YoY to Rs. 538.4 cr: Edelweiss

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

  • Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

  • Cadila Q4 PAT seen up 19.5% to Rs 309.7 cr: ICICI Securities

Advisory Alert:

It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347